|
Jul 26
|
Bristol Myers Stock Rises Sharply. A Sales Jump for Eliquis Boosts Earnings.
|
|
Jul 26
|
PCE/Core PCE Inflation In Line With Estimates in June
|
|
Jul 26
|
Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
|
|
Jul 26
|
Pre-Markets Swell, PCE Behaves, Several Q2 Beats
|
|
Jul 26
|
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
|
|
Jul 26
|
Bristol Myers (BMY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Jun 27
|
Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
|
|
Jun 25
|
BMS expands Krazati’s FDA label to include colorectal cancer
|
|
Jun 24
|
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
|
|
Jun 24
|
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
|
|
Jun 22
|
3 No-Brainer Stocks to Buy for Under $100 Right Now
|
|
Jun 22
|
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
|
|
Jun 21
|
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
|
|
Jun 21
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
|
|
Jun 20
|
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
|
|
Jun 11
|
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
|
|
Jun 8
|
Bristol-Myers Squibb Insiders Sold US$1.1m Of Shares Suggesting Hesitancy
|
|
Jun 7
|
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
|
|
Jun 6
|
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
|
|
Jun 5
|
Here’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
|